KRAS-driven lung cancers represent an aggressive form of NSCLC. In this study the authors perform an in vivo functional screening and identify GATAD2B as a driver of tumor growth and metastasis in KRAS-driven lung cancer.
- Caitlin L. Grzeskowiak
- Samrat T. Kundu
- Kenneth L. Scott